James Cloyd, PharmD
Disclosures: Consulting Fee-Current-Neurelis|Receipt of Intellectual Property Rights/Patent Holder-Current-Ligand|Consulting Fee-Current-UCB|Consulting Fee-April 30, 2019-Cerebral Therapeutics|Consulting Fee-May 31, 2019-Engage|Consulting Fee-May 31, 2019-Supernus
No Bio Available.